Cyclerion Therapeutics, Inc. (CYCN): Price and Financial Metrics
GET POWR RATINGS... FREE!
CYCN POWR Grades
- Growth is the dimension where CYCN ranks best; there it ranks ahead of 86.53% of US stocks.
- The strongest trend for CYCN is in Momentum, which has been heading down over the past 48 weeks.
- CYCN's current lowest rank is in the Stability metric (where it is better than 4.68% of US stocks).
CYCN Stock Summary
- Cyclerion Therapeutics Inc's stock had its IPO on March 18, 2019, making it an older stock than merely 6.08% of US equities in our set.
- CYCN's price/sales ratio is 42.01; that's higher than the P/S ratio of 94.15% of US stocks.
- With a year-over-year growth in debt of -93.33%, Cyclerion Therapeutics Inc's debt growth rate surpasses just 2.31% of about US stocks.
- Stocks that are quantitatively similar to CYCN, based on their financial statements, market capitalization, and price volatility, are BLUE, CLSD, BCDA, ACET, and SWTX.
- CYCN's SEC filings can be seen here. And to visit Cyclerion Therapeutics Inc's official web site, go to www.cyclerion.com.
CYCN Valuation Summary
- In comparison to the median Healthcare stock, CYCN's price/earnings ratio is 106.03% lower, now standing at -2.2.
- CYCN's price/earnings ratio has moved down 0.5 over the prior 30 months.
- CYCN's price/earnings ratio has moved down 0.5 over the prior 30 months.
Below are key valuation metrics over time for CYCN.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| CYCN | 2021-08-31 | 41.2 | 2.3 | -2.2 | -1.2 |
| CYCN | 2021-08-30 | 38.3 | 2.1 | -2.0 | -1.0 |
| CYCN | 2021-08-27 | 39.8 | 2.2 | -2.1 | -1.1 |
| CYCN | 2021-08-26 | 38.3 | 2.1 | -2.0 | -1.0 |
| CYCN | 2021-08-25 | 36.7 | 2.0 | -2.0 | -1.0 |
| CYCN | 2021-08-24 | 36.7 | 2.0 | -2.0 | -1.0 |
CYCN's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- CYCN has a Quality Grade of C, ranking ahead of 48.5% of graded US stocks.
- CYCN's asset turnover comes in at 0.034 -- ranking 346th of 677 Pharmaceutical Products stocks.
- 500 - Internal server error
The table below shows CYCN's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.034 | 1 | -0.991 |
| 2021-03-31 | 0.011 | 1 | -0.741 |
| 2020-12-31 | 0.018 | 1 | -0.770 |
| 2020-09-30 | 0.025 | 1 | -0.733 |
| 2020-06-30 | 0.028 | 1 | -0.734 |
| 2020-03-31 | 0.029 | 1 | -0.788 |
CYCN Price Target
For more insight on analysts targets of CYCN, see our CYCN price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $4.00 | Average Broker Recommendation | 2 (Hold) |
CYCN Stock Price Chart Interactive Chart >
CYCN Price/Volume Stats
| Current price | $3.38 | 52-week high | $7.55 |
| Prev. close | $3.49 | 52-week low | $2.08 |
| Day low | $3.29 | Volume | 577,600 |
| Day high | $3.62 | Avg. volume | 877,040 |
| 50-day MA | $3.19 | Dividend yield | N/A |
| 200-day MA | $3.37 | Market Cap | 146.28M |
Cyclerion Therapeutics, Inc. (CYCN) Company Bio
Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of various treatments for serious and orphan diseases. Its product candidates include Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator that is in Phase II studies for the treatment of sickle cell disease (SCD); Praliciguat, an orally administered systemic sGC stimulator that is in Phase II trials for the treatment of diabetic nephropathy and heart failure with preserved ejection fraction; and IW-6463, an orally administered central nervous system (CNS)-penetrant sGC stimulator, which is in Phase I trials for neurodegenerative diseases. The company is also discovering liver-targeted sGC and lung-targeted sGC stimulators. Cyclerion Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
Latest CYCN News From Around the Web
Below are the latest news stories about Cyclerion Therapeutics Inc that investors may wish to consider to help them evaluate CYCN as an investment opportunity.
Cyclerion Announces Publication of Preclinical Data Demonstrating Reduction in Neuroinflammation by Brain-Penetrant sGC StimulatorCompany developing lead sGC stimulator, CY6463, in multiple CNS diseases associated with cognitive impairmentCAMBRIDGE, Mass., Sept. 22, 2021 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company developing treatments that restore cognitive function, today announced a publication demonstrating that administration of a small molecule soluble guanylate cyclase (sGC) stimulator reduced markers associated with neuroinflammation in multiple precli |
Cyclerion Therapeutics to Participate in Two Upcoming Investor ConferencesCAMBRIDGE, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function, today announced that Company management will present at two upcoming investor conferences. H.C. Wainwright 23rd Annual Global Investment Conference September 13-15, 2021. On-demand session is available starting at 7:00 a.m. EDT on September 13th.Cantor Fitzgerald Virtual Global Healthcare C |
Cyclerion Therapeutics (NASDAQ:CYCN) Has Debt But No Earnings; Should You Worry?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the... |
Cyclerion Therapeutics to Present at Annual Biomarkers for Alzheimer’s Disease SummitPresentation to highlight the potential of early clinical assessment of biomarkers to drive development of Alzheimer’s disease therapiesCAMBRIDGE, Mass., Aug. 23, 2021 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function, today announced participation in the Annual Biomarkers for Alzheimer’s Disease Summit taking place virtually August 25-26, 2021. Chris Winrow, Ph.D., Head o |
Cyclerion Therapeutics Reports Second Quarter 2021 Financial Results and Corporate UpdateContinuing to progress clinical development of CY6463, a first-in-class, CNS-penetrant soluble guanylate cyclase (sGC) stimulator for the treatment of neurological diseases associated with cognitive impairment Advancing CY3018, a differentiated, next-generation, CNS-penetrant sGC stimulator, in IND-enabling studies CAMBRIDGE, Mass., July 29, 2021 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments that res |
CYCN Price Returns
| 1-mo | 2.11% |
| 3-mo | -18.36% |
| 6-mo | 25.65% |
| 1-year | -50.29% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 10.46% |
| 2020 | 12.50% |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
| 2016 | N/A |
Loading social stream, please wait...